Vascular endothelial growth factor A inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor: Overview
The VEGF (vascular endothelial growth factor) pathway has emerged as an important target for cancer therapy, with VEGF signaling pathway (VSP) inhibitors having been approved for several different malignancies. The human VEGF family consists of 5 related glycoproteins: VEGFA, VEGFB, VEGFC, VEGFD, and PIGF (placental growth factor). These are secreted to form homodimers, which interact with a family of 3 receptor tyrosine kinases: VEGFR1 (VEGF receptor 1), VEGFR2, and VEGFR3. VEGFA and VEGFB bind to VEGFR1, VEGFA binds to VEGFR2, and VEGFC and VEGFD bind to both VEGFR2 and VEGFR3.
VSP inhibitors have been found to reduce NO pathway metabolites and NO-dependent processes. Inhibition of VEGF pathway is a strategy being widely pursued to provide new therapeutics for the treatment of VEGF related disorders.
Novel antiangiogenic cancer therapies, particularly agents that block vascular endothelial growth factor (VEGF) signalling, have improved outcomes in patients with cancers and are now used as first-line therapies for some tumours. However, with VEGF inhibitors (VEGFIs) are new complications, particularly hypertension. VEGFI-induced hypertension is a dose-dependent phenomenon due to on-target effects rather than off-target effects.
Report Highlights
This segment of the Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Emerging Drugs
It is currently in the Phase III stage of development for the treatment of wAMD and is being developed by Sandoz, a division of Novartis.
It is currently in Phase II stage of development and is being developed by Viking Therapeutics.
Further product details are provided in the report……..
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor drugs.
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor: Overview
The VEGF (vascular endothelial growth factor) pathway has emerged as an important target for cancer therapy, with VEGF signaling pathway (VSP) inhibitors having been approved for several different malignancies. The human VEGF family consists of 5 related glycoproteins: VEGFA, VEGFB, VEGFC, VEGFD, and PIGF (placental growth factor). These are secreted to form homodimers, which interact with a family of 3 receptor tyrosine kinases: VEGFR1 (VEGF receptor 1), VEGFR2, and VEGFR3. VEGFA and VEGFB bind to VEGFR1, VEGFA binds to VEGFR2, and VEGFC and VEGFD bind to both VEGFR2 and VEGFR3.
VSP inhibitors have been found to reduce NO pathway metabolites and NO-dependent processes. Inhibition of VEGF pathway is a strategy being widely pursued to provide new therapeutics for the treatment of VEGF related disorders.
Novel antiangiogenic cancer therapies, particularly agents that block vascular endothelial growth factor (VEGF) signalling, have improved outcomes in patients with cancers and are now used as first-line therapies for some tumours. However, with VEGF inhibitors (VEGFIs) are new complications, particularly hypertension. VEGFI-induced hypertension is a dose-dependent phenomenon due to on-target effects rather than off-target effects.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor R&D. The therapies under development are focused on novel approaches for Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor.
This segment of the Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Emerging Drugs
- SOK583A1: Sandoz
It is currently in the Phase III stage of development for the treatment of wAMD and is being developed by Sandoz, a division of Novartis.
- VK-2809: Viking Therapeutics
It is currently in Phase II stage of development and is being developed by Viking Therapeutics.
Further product details are provided in the report……..
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor drugs.
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Report Insights
- Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor drugs?
- How many Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor and their status?
- What are the key designations that have been granted to the emerging drugs?
- Sandoz
- Sam Chun Dang Pharm
- Samsung Bioepis
- Luye Pharma
- Shanghai Henlius Biotech
- Generium Pharmaceuticals
- Bioeq GmbH
- Roche
- Chong Kun Dang Pharmaceutical
- Outlook Therapeutics
- Qilu Pharmaceuticals
- AngioLab
- Sinocelltech
- Alteogen
- Adverum Biotechnologies
- Boehringer Ingelheim
- Eyevensys
- Oxford BioMedica
- SOK583A1
- SCD411
- SB15
- LY09004
- HLX04-O
- GNR-067
- Faricimab
- FYB203
- CKD-701
- ONS-5010
- BCD 300
- ALS-L1023
- SCT510A
- ALT-L9
- ADVM-022
- BI 836880
- EYS609
- OXB-203
Introduction
Executive Summary
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor : Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
SOK583A1: Sandoz
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
ALS-L1023: AngioLab
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
ALT-L9: Alteogen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
EYS609: Eyevensys
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Key Companies
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Key Products
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor - Unmet Needs
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor - Market Drivers and Barriers
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor - Future Perspectives and Conclusion
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Analyst Views
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Key Companies
Appendix
Executive Summary
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor : Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
SOK583A1: Sandoz
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
ALS-L1023: AngioLab
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
ALT-L9: Alteogen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
EYS609: Eyevensys
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Key Companies
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Key Products
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor - Unmet Needs
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor - Market Drivers and Barriers
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor - Future Perspectives and Conclusion
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Analyst Views
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Vascular endothelial growth factor A inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Vascular endothelial growth factor A inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Vascular endothelial growth factor A inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Vascular endothelial growth factor A inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
